Insys Therapeutics Reports Record Third Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Insys Therapeutics Reports Record Third Quarter 2015 Results
November 6, 2015 9:57 AM EST
Piper Jaffray reiterated an Overweight rating on INSYS Therapeutics (NASDAQ: INSY), and raised the price target to $49.00 (from $48.00), following the company's 3Q15 earnings report. Insys reported 3Q15 EPS of $0.50, on revenues of $91M, well ahead of Street estimates. Subsys once again showed strong sequential growth, with sequential sales growth of 19% over 2Q15. Management suggested... More
November 5, 2015 8:00 AM EST
Insys Therapeutics (NASDAQ: INSY) reported Q3 EPS of $0.50, $0.27 better than the analyst estimate of $0.23. Revenue for the quarter came in at $91.3 million versus the consensus estimate of $82.98 million.
For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.
...
More
November 5, 2015 6:59 AM EST
Insys Therapeutics, Inc. (NASDAQ: INSY) announced that Michael L. Babich has stepped down as President and Chief Executive Officer of Insys. The Board of Directors has appointed Dr. John N. Kapoor as President and Chief Executive Officer effective November 4, 2015. Dr. Kapoor will continue to serve of the Chairman of the Companys Board of Directors. Daniel Brennan has been appointed Executive Vice President and Chief Operating Officer effective November 1, 2015.
It has been a privilege to lead Insys for the past six... More
